Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiency‐related ichthyosis in a child

• Main Authors: J. Yogarajah (Author), C. Gouveia (Author), J. Iype (Author), S. Häfliger (Author), A. Schaller (Author), J.M. Nuoffer (Author), M. Fux (Author), M. Gautschi (Author)
• Format: Book
• Published: Wiley, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary Background Patients with severe autosomal recessive congenital ichthyosis (ARCI) show a T helper 17/interleukin 17 (Th17/IL17) skewing in their skin and serum, resembling the inflammatory profile of psoriatic patients. Secukinumab, an IL‐17A inhibitor, has shown clinical efficacy in patients...